Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

Nature Medicine

Volumn 22, Issue 4, 2016, Pages 369-378

  Kumar, Akash ^a   Coleman, Ilsa ^b   Morrissey, Colm ^c   Zhang, Xiaotun ^c   True, Lawrence D ^a   Gulati, Roman ^b   Etzioni, Ruth ^b   Bolouri, Hamid ^b   Montgomery, Bruce ^a   White, Thomas ^b   Lucas, Jared M ^b   Brown, Lisha G ^c   Dumpit, Ruth F ^b   DeSarkar, Navonil ^b   Higano, Celestia ^a   Yu, Evan Y ^a   Coleman, Roger ^b   Schultz, Nikolaus ^d   Fang, Min ^a,b   Lange, Paul H ^c   Shendure, Jay ^a   Vessella, Robert L ^c   Nelson, Peter S ^a,b,c   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CARBOPLATIN; DNA; DOCETAXEL; PROTEIN SERINE THREONINE KINASE; RNA; TESTOSTERONE; TRANSCRIPTION FACTOR E2F1; ATM PROTEIN; ATM PROTEIN, HUMAN; E2F1 PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CELL ACTIVITY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISSEMINATED CANCER; DNA REPAIR; EXOME; FANCONI ANEMIA; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETINOBLASTOMA; RNA TRANSCRIPTION; SOMATIC MUTATION; TREATMENT RESPONSE; ADULT; AGED; BIOSYNTHESIS; COPY NUMBER VARIATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; HUMAN GENOME; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS;

ADULT; AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARBOPLATIN; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN;

EID: 84959255550     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4053     Document Type: Article

References (54)

1. National Research Council (U.S.). Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. (National Academies Press, 2011
2. Perou, C.M., et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000
3. Frattini, V., et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013
4. Sato, Y., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860-867 (2013
5. Verhaak, R.G., et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517-525 (2013
6. Tannock, I.F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004
7. de Bono, J.S., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011
8. Scher, H.I., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012
9. Druker, B.J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566 (1996
10. Yachida, S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010
11. Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
12. Cooper, C.S., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367-372 (2015
13. Liu, W., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009
14. Haffner, M.C., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918-4922 (2013
15. Gundem, G., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015
16. Siegel, R.L., Miller, K.D., & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
17. Huggins, C., & Hodges, C.V. Studies on prostate cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941
18. Kumar, A., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 108, 17087-17092 (2011
19. Grasso, C.S., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012
20. Robinson, D., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015
21. Mosquera, J.M., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1-10 (2013
22. Qi, J., et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18, 23-38 (2010
23. Gupta, A., et al Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Prostate 73, 582-589 (2013
24. Pritchard, C.C., et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 5, 4988 (2014
25. Hieronymus, H., et al. Copy number alteration burden predicts prostate cancer relapse. Proc. Natl. Acad. Sci. USA 111, 11139-11144 (2014
26. Taylor, B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010
27. Sahu, B., et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 73, 1570-1580 (2013
28. Arora, V.K., et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013
29. Lai, J., Myers, S.A., Lawrence, M.G., Odorico, D.M., & Clements, J.A. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol. Cancer Res. 7, 129-141 (2009
30. Setlur, S.R., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl. Cancer Inst. 100, 815-825 (2008
31. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015
32. Tomlins, S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005
33. Morrissey, C., et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin. Exp. Metastasis 25, 377-388 (2008
34. Cuzick, J., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245-255 (2011
35. Sedelaar, J.P., & Isaacs, J.T. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 69, 1724-1729 (2009
36. Kokontis, J.M., Hay, N., & Liao, S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12, 941-953 (1998
37. Schweizer, M.T., et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci. Transl. Med. 7, 269ra2 (2015
38. Tategu, M., Arauchi, T., Tanaka, R., Nakagawa, H., & Yoshida, K. Systems biology-based identification of crosstalk between E2F transcription factors and the Fanconi anemia pathway. Gene Regul. Syst. Bio. 1, 1-8 (2007
39. Meier, D., & Schindler, D. Fanconi anemia core complex gene promoters harbor conserved transcription regulatory elements. PLoS One 6, e22911 (2011
40. Tan, H.L., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890-903 (2014
41. Mateo, J., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697-1708 (2015
42. Lindberg, J., et al. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur. Urol. 63, 702-708 (2013
43. Barbieri, C.E., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012
44. Robbins, C.M., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 21, 47-55 (2011
45. Aryee, M.J., et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 169ra10 (2013
46. de Bruin, E.C., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
47. McKenna, A., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010
48. Wu, X., et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529-533 (2012
49. Zhang, J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014
50. Sakr, W.A., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8, 439-443 (1994
51. Garraway, L.A., & Sellers, W.R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 6, 593-602 (2006
52. Jones, M.J., & Huang, T.T. The Fanconi anemia pathway in replication stress and DNA crosslink repair. Cell. Mol. Life Sci. 69, 3963-3974 (2012
53. Roudier, M.P., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 34, 646-653 (2003
54. Li, H., et al., & 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009